Table 1 Participant demographics
Participant cohort (n = 67) | |
|---|---|
Male | 30 (44.8%) |
Age (yrs) | 30 (25–41) |
BNT162b2 Vaccine | 59 (88.1%) |
CoronaVac Vaccine | 8 (11.9%) |
No. of Days between 1st vaccination and 1st CMR Scan Examination (days) | 4 (1–8) |
No. of Days between 2nd vaccination and 2nd CMR Scan Examination (days) | 4.7 \(\pm\) 2.4 |
Days between 1st and 2nd Vaccine Dose (days) | 24 (21–28) |
1st Vaccination Injected into the Left Arm | 60 (89.6%) |
1st Vaccination Injected into the Right Arm | 5 (7.5%) |
1st Vaccination Injected into the Left Thigh | 2 (3.0%) |
2nd Vaccination Injected into the Left Arm | 60 (89.6%) |
2nd Vaccination Injected into the Right Arm | 5 (7.5%) |
2nd Vaccination Injected into the Left Thigh | 2 (3.0%) |
Symptoms after 2nd COVID-19 Vaccination Dose | |
Chest pain | 15 (22.4%) |
Vomiting | 0 (0.0%) |
Nausea | 4 (6.0%) |
Pyrexia (≥ 38\(^{{^{ \circ } }}\)C) | 6 (9.0%) |
Myalgia | 37 (55.2%) |
Fatigue | 33 (49.3%) |
Shortness of breath | 11 (16.4%) |
Palpitations | 7 (10.4%) |
Cardiac risk factors & Co-Morbidities | |
Hypertension | 4 (6.0%) |
Hyperlipidaemia | 4 (6.0%) |
Obesity | 1 (1.5%) |
Smoking | 3 (4.5%) |
Diabetes Mellites Type 2 | 2 (3.0%) |
Previous CABG | 0 (0.0%) |
Previous coronary stent | 0 (0.0%) |
Previous history of cancer | 0 (0.0%) |
Drugs | |
ACEI/ ARB | 1 (1.5%) |
Beta-blockers | 2 (3.0%) |
Calcium channel blockers | 2 (3.0%) |
Diuretics | 0 (0.0%) |
Clopidogrel | 0 (0.0%) |
Aspirin | 1 (1.5%) |
Anti-diabetic | 0 (0.0%) |
Statin | 4 (6.0%) |